We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePhase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerAuthorsKrop, Ian E.; Beeram, Muralidhar; Modi, Shanu; Jones, Suzanne F.; Holden, Scott N.; Yu, Wei; Girish, Sandhya; Tibbitts, Jay; Yi, Joo-Hee; Sliwkowski, Mark X.; Jacobson, Fred; Lutzker, Stuart G.; Burris, Howard A.PublicationJournal of Clinical Oncology, 2010, Vol 28, Issue 16, p2698ISSN0732-183xPublication typearticleDOI10.1200/jco.2009.26.2071